D-0053-2015 Class III Terminated

Recalled by Valeant Pharmaceuticals North America LLC — Bridgewater, NJ

FDA drug recall D-0053-2015 was initiated by Valeant Pharmaceuticals North America LLC on Jun 5, 2014 and is designated Class III. Reason for recall: Labeling: Incorrect or Missing Package Insert The recall status is terminated (terminated Jul 27, 2017). Affected quantity: 55,650 HDPE bottles.

Recall details

Product Type
Drugs
Report Date
Nov 5, 2014
Initiation Date
Jun 5, 2014
Termination Date
Jul 27, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
55,650 HDPE bottles

Product description

APLENZIN¿ (bupropion hydrobromide), extended-release tablets, 522 mg, a) 7-count HDPE bottle (NDC 0024-5812-07), b) 30-count HDPE bottle (NDC 0024-5812-30), Rx Only, Manufactured by Valeant Pharmaceuticals International, Inc. Steinbach MB, Canada R5G 1Z7

Reason for recall

Labeling: Incorrect or Missing Package Insert

Distribution pattern

Nationwide

Code information

Lot #: a) 13E023P; Exp. 03/16 Lot #: b) 12J063P; Exp. 07/15 12K063P; Exp. 09/15 12K060P; Exp. 07/15 12M073P; Exp. 09/15 13A036P; Exp. 11/15 13B035P; Exp. 11/15 13C046P; Exp. 11/15 13D060P; Exp. 11/15 13E030P; Exp. 03/16 13E031P; Exp. 03/16 13F003P; Exp. 03/16 13K034P; Exp. 03/16 14A001P; Exp. 10/16

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0053-2015
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0053-2015. Report a data issue: hello@regdatalab.com.